TY  - JOUR

T1  - LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)

JO  - Annals of Oncology

PY  - 2021/09/01

AU  - Vasudev NS

AU  - Ainsworth G

AU  - Brown S

AU  - Pickering L

AU  - Waddell TS

AU  - Fife K

AU  - Griffiths R

AU  - Sharma A

AU  - Katona E

AU  - Howard H

AU  - Velikova G et al

ED  - 

DO  - DOI: 10.1016/j.annonc.2021.08.2105

PB  - Elsevier BV

VL  - 32

SP  - S1304

EP  - S1305

Y2  - 2024/12/21

ER  -